Levels Of Institutional Ownership At Audentes Therapeutics, Inc. (BOLD)

Audentes Therapeutics, Inc. (NASDAQ:BOLD) has made a 44.12% comeback from a 12-month low price of $17.95. It was seen 4.78% higher, changing the price to $25.87, when the closing bell rang on 01/11/2019. At recent session, the prices were hovering between $24.985 and $26.84. This company shares are 49.36% off its target price of $38.64 and the current market capitalization stands at $1.05B. The recent change has given its price a 9.26% lead over SMA 50 and -43.98% deficit over its 52-week high. The stock witnessed 10.18% gains, -13.26% declines and -32.35% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BOLD’s volatility during a week at 7.01% and during a month it has been found around 7.73%.

Audentes Therapeutics, Inc. (BOLD) Top Holders

Institutional investors currently hold around $935 million or 94.1% in BOLD stock. Look at its top three institutional owners. Fmr Llc owns $100.8 million in Audentes Therapeutics, Inc., which represents roughly 9.6% of the company’s market cap and approximately 10.78% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 3,303,402 shares of the stock are valued at $85.46 million. The third largest holder is Blackrock Inc., which currently holds $66.43 million worth of this stock and that ownership represents nearly 6.33% of its market capitalization.

Audentes Therapeutics, Inc. 13F Filings

At the end of September reporting period, 55 institutional holders increased their position in Audentes Therapeutics, Inc. (NASDAQ:BOLD) by some 3,652,026 shares, 52 decreased positions by 3,544,456 and 26 held positions by 28,940,490. That puts total institutional holdings at 36,136,972 shares, according to SEC filings. The stock grabbed 10 new institutional investments totaling 765,057 shares while 21 institutional investors sold out their entire positions totaling 1,568,336 shares.

Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insider Trades

Multiple company employees have indulged in significant insider trading. Audentes Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Lange Louis G has sold 32,000 shares of Audentes Therapeutics, Inc. (BOLD) in trading session dated Dec. 24, 2018. These shares are worth $595,840 and were traded at $18.62 each. The SEC filing shows that Lange Louis G performed a sale of 24,000 shares. The Director disposed these shares by way of transaction on Nov. 15, 2018. The company’s shares were given away at $22.49 per share worth to an income of some $539,760 on account of Lange Louis G.

Director, Lange Louis G, sold 33,000 common shares of Audentes Therapeutics, Inc. (BOLD) in the open market. In a transaction dated Sep. 24, 2018, the shares were put up for sale at an average price of $37.38, raking in a sum of $1,233,540. After this sale, 435,933 common shares of BOLD are directly owned by the insider, with total stake valued at $11,277,587.

In the transaction dated Sep. 18, 2018, the great number of shares disposed came courtesy the CEO; Patterson Matthew R disposed a total of 12,952 shares at an average price of $40, amounting to approximately $518,080. The insider now directly owns 171,814 shares worth $4,444,828.

Audentes Therapeutics, Inc. (BOLD) Analyst Guide

Several analysts have released their opinion on Audentes Therapeutics, Inc. (NASDAQ:BOLD), with 3 analysts believing it is a strong buy. Whereas 6 of them predict the stock is a hold. Also, there are 6 buy, 1 sell and 0 strong sell ratings, collectively assigning a 2.31 average brokerage recommendation.